Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: I imagine many here saw what I would consider

Remember...The that Crossflow preferred shareholders received 17,583,235 PTSC shares to complete the acquisition back in September of last year. I believe that they have a vested interested to secure a GOOD return for their investment; otherwise, the company may NOT retain its most valuable assets, developers of the product. IMO, any acquisition of PTSG should be good for shareholders.

Share
New Message
Please login to post a reply